Ke He (何锞)
Deputy Director & Head of Skin & Laser Aesthetics · Attending Physician, Licensed Aesthetic Attending · Lead Physician of This Site
Reading regenerative claims against the authorisation behind them · unapproved cell and exosome products · the established options beside them
Dr. Ke He is Deputy Director of the Plastic Surgery & Aesthetics Medical Center at Chongqing West District Hospital and head of its skin and laser aesthetic service — and she is the lead physician of this site. A core specialist formerly at the Plastic and Aesthetic Surgery Department of Xinqiao Hospital, affiliated with Army Medical University, she has worked on the clinical front line in skin laser and injectable aesthetics for more than 20 years, serving over ten thousand patients.
On this review his part is the distinction between a word and an authorisation. He treats regenerative as a description that carries no regulatory weight, and he asks of any product what it is authorised for, in which market, and by whom, rather than what it is said to do. Where the answer is that a product is not authorised at all, he says so plainly, because that is the fact that decides most of the question and it is the one most often left out. He grades the members of the group separately rather than as a class, describes the survival of injected cells as the poor finding it is, and where a person wants a change in appearance he starts from the options with known risk profiles rather than from the newest description available.
Clinical focus
Academic roles & achievements
A word is not an authorisation
No authority approves a material as regenerative, because the word describes an intention rather than a composition or an indication. That is why the members of this group are approved or not approved one at a time, and why a page organised around the word rather than the products has already lost the question.
